PharmaBlock Sciences Nanjing Inc
SZSE:300725

Watchlist Manager
PharmaBlock Sciences Nanjing Inc Logo
PharmaBlock Sciences Nanjing Inc
SZSE:300725
Watchlist
Price: 35.78 CNY 1.07%
Market Cap: 7.1B CNY
Have any thoughts about
PharmaBlock Sciences Nanjing Inc?
Write Note

PharmaBlock Sciences Nanjing Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

PharmaBlock Sciences Nanjing Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
PharmaBlock Sciences Nanjing Inc
SZSE:300725
Revenue
ÂĄ1.6B
CAGR 3-Years
9%
CAGR 5-Years
21%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Revenue
ÂĄ10.1B
CAGR 3-Years
5%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Revenue
ÂĄ10.9B
CAGR 3-Years
13%
CAGR 5-Years
15%
CAGR 10-Years
23%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Revenue
ÂĄ26B
CAGR 3-Years
-3%
CAGR 5-Years
3%
CAGR 10-Years
14%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Revenue
ÂĄ39.3B
CAGR 3-Years
2%
CAGR 5-Years
7%
CAGR 10-Years
8%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Revenue
ÂĄ561.9m
CAGR 3-Years
-18%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

PharmaBlock Sciences Nanjing Inc
Glance View

Market Cap
7.1B CNY
Industry
Pharmaceuticals

PharmaBlock Sciences (Nanjing), Inc. engages in the innovation of chemistry products and services throughout the pharmaceutical research and development process. The company is headquartered in Nanjing, Jiangsu and currently employs 1,735 full-time employees. The company went IPO on 2017-11-10. The firm's primary products include aromatic heterocyclic drug molecular building blocks, common saturated alicyclic drug molecular building blocks, four-membered ring drug molecular building blocks and special saturated ring drug molecular building blocks. The firm is also involved in development, production and sales of pharmaceutical intermediates, and provides technical services related to the development and process production of pharmaceutical molecular building blocks.

Intrinsic Value
54.21 CNY
Undervaluation 34%
Intrinsic Value
Price

See Also

What is PharmaBlock Sciences Nanjing Inc's Revenue?
Revenue
1.6B CNY

Based on the financial report for Sep 30, 2024, PharmaBlock Sciences Nanjing Inc's Revenue amounts to 1.6B CNY.

What is PharmaBlock Sciences Nanjing Inc's Revenue growth rate?
Revenue CAGR 5Y
21%

Over the last year, the Revenue growth was -8%. The average annual Revenue growth rates for PharmaBlock Sciences Nanjing Inc have been 9% over the past three years , 21% over the past five years .

Back to Top